Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.020 GeneticVariation BEFREE Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients with lung cancer has been linked to acquisition of the T790M resistance mutation in activated EGFR or amplification of MET. 23592446

2013
dbSNP: rs121434569
rs121434569
EGFR ; EGFR-AS1
0.020 GeneticVariation BEFREE Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET. 19351834

2009
dbSNP: rs1057519825
rs1057519825
BTK
0.010 GeneticVariation BEFREE Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutants, which facilitate clinical resistance to ibrutinib.<b>Significance:</b> This study characterizes a rationally designed kinase inhibitor with efficacy in models recapitulating the most common mechanisms of acquired resistance to ibrutinib. 30093506

2018
dbSNP: rs1057519826
rs1057519826
BTK
0.010 GeneticVariation BEFREE Additionally, ARQ 531 inhibits CLL cell survival and suppresses BCR-mediated activation of C481S BTK and PLCγ2 mutants, which facilitate clinical resistance to ibrutinib.<b>Significance:</b> This study characterizes a rationally designed kinase inhibitor with efficacy in models recapitulating the most common mechanisms of acquired resistance to ibrutinib. 30093506

2018
dbSNP: rs1057519783
rs1057519783
ALK
0.010 GeneticVariation BEFREE Early data point to <i>ALK</i> G1202R and <i>ALK</i> E1210K as potential mechanisms of clinical resistance to brigatinib. 28435288

2017
dbSNP: rs113488022
rs113488022
BRAF
0.010 GeneticVariation BEFREE Acquired clinical resistance to vemurafenib, a selective BRAF(V600E) inhibitor, arises frequently after short-term chemotherapy. 24249714

2014
dbSNP: rs121913377
rs121913377
BRAF
0.010 GeneticVariation BEFREE Acquired clinical resistance to vemurafenib, a selective BRAF(V600E) inhibitor, arises frequently after short-term chemotherapy. 24249714

2014
dbSNP: rs121913459
rs121913459
ABL1
0.010 GeneticVariation BEFREE However, our study indicates that clinical resistance to nilotinib may be associated with the predominant emergence of T315I. 16614241

2006
dbSNP: rs748843032
rs748843032
MTTP
0.010 GeneticVariation BEFREE However, our study indicates that clinical resistance to nilotinib may be associated with the predominant emergence of T315I. 16614241

2006
dbSNP: rs1045642
rs1045642
ABCB1
0.010 GeneticVariation BEFREE We hypothesized that clinical resistance to 5-HT(3) antagonists is associated with the single-nucleotide polymorphism (3435C>T) in the gene that codes for the drug efflux transporter adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1). 16338277

2005